United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $50.54 Million Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• United Super reduced its Merck stake by 21.3% in the second quarter, selling 106,500 shares and retaining 393,305 shares valued at approximately $50.54 million. Institutional investors collectively own 76.07% of MRK.
• Merck and Moderna’s personalized cancer therapy achieved key Phase 3 goals in high-risk melanoma, strengthening the outlook for Keytruda-based oncology growth and prompting several analysts to raise price targets. However, RBC Capital Markets and Jefferies cited valuation, execution risks and Keytruda’s 2028 patent expiration in downgrades.
• Merck reported quarterly revenue of $16.61 billion, up 5.1% year over year, and exceeded analysts’ EPS expectations; it also declared a quarterly dividend of $0.85 per share, representing a 2.2% annualized yield.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund trimmed its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 21.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 393,305 shares of the company's stock after selling 106,500 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's holdings in Merck & Co., Inc. were worth $50,540,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRK. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at about $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. High Note Wealth LLC grew its stake in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Insider Activity

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares of the company's stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company's stock.

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research reports. Wells Fargo & Company raised their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 8th. Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley raised Merck & Co., Inc. from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $116.00 to $179.00 in a research note on Thursday. CICC Research initiated coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price for the company. Finally, Bank of America upped their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Fifteen analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average target price of $144.10.

Merck & Co., Inc. Stock Performance

MRK stock opened at $152.43 on Monday. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $154.49. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The firm has a market cap of $376.07 billion, a PE ratio of 121.94, a P/E/G ratio of 6.40 and a beta of 0.19. The business's 50-day moving average price is $128.09 and its two-hundred day moving average price is $121.29.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio is presently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source